Log in to save to my catalogue

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Ef...

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Ef...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1719284499

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?

About this item

Full title

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?

Publisher

United States: Public Library of Science

Journal title

PloS one, 2015-09, Vol.10 (9), p.e0133907

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

The goal of this study was to determine how the choice of the primary endpoint influenced sample size estimates in randomised controlled trials (RCTs) of treatments for primary Sjögren's syndrome (pSS).
We reviewed all studies evaluating biotechnological therapies in pSS to identify their inclusion criteria and primary endpoints. Then, in a larg...

Alternative Titles

Full title

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_1719284499

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1719284499

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0133907

How to access this item